Abstract
Introduction: While a patent ductus arteriosus (PDA) helps offload the right ventricle in the acute congenital diaphragmatic hernia (CDH)-associated pulmonary hypertension, its role on long-term outcomes in CDH has not been investigated. Our objective was to examine associations of the PDA with long-term clinical outcomes in CDH. Methods: A single-center retrospective descriptive study of 122 CDH patients dichotomized by duration with PDA, as ≤14 versus >14 postnatal days (PND) and ≤30 versus >30 PND. Fisher’s exact test, Wilcoxon rank-sum test, and multiple linear and logistic regression analyses were used for analyses. Results: In unadjusted and adjusted for CDH severity comparisons, patients with PDA >14 PND and >30 PND had a higher risk of death, longer length of stay, mechanical ventilation duration, and need for tracheostomy, diuretics, and PH medications at discharge. Conclusion: A PDA beyond the newborn period is associated with adverse outcomes in infants with CDH.
Journal Section:
Original Paper
References
1.
Gupta
VS
, Harting
MT
. Congenital diaphragmatic hernia-associated pulmonary hypertension
. Semin Perinatol
. 2020
;44
(1
):151167
. 2.
Lusk
LA
, Wai
KC
, Moon-Grady
AJ
, Steurer
MA
, Keller
RL
. Persistence of pulmonary hypertension by echocardiography predicts short-term outcomes in congenital diaphragmatic hernia
. J Pediatr
. 2015
;166
(2
):251
–6.e1
. 3.
Snoek
KG
, Reiss
IK
, Greenough
A
, Capolupo
I
, Urlesberger
B
, Wessel
L
, et al. Standardized postnatal management of infants with congenital diaphragmatic hernia in Europe: the CDH EURO consortium consensus-2015 update
. Neonatology
. 2016
;110
(1
):66
–74
. 4.
Salas
GL
, Otaño
JC
, Cannizzaro
CM
, Mazzucchelli
MT
, Goldsmit
GS
. Congenital diaphragmatic hernia: postnatal predictors of mortality
. Arch Argent Pediatr
. 2020
;118
(3
):173
–9
. 5.
Kinsella
JP
, Steinhorn
RH
, Mullen
MP
, Hopper
RK
, Keller
RL
, Ivy
DD
, et al. The left ventricle in congenital diaphragmatic hernia: implications for the management of pulmonary hypertension
. J Pediatr
. 2018
;197
:17
–22
. 6.
Scott
DA
, Gofin
Y
, Berry
AM
, Adams
AD
. Underlying genetic etiologies of congenital diaphragmatic hernia
. Prenat Diagn
. 2022
;42
(3
):373
–86
. 7.
Pober
BR
. Overview of epidemiology, genetics, birth defects, and chromosome abnormalities associated with CDH
. Am J Med Genet C Semin Med Genet
. 2007
;145C
(2
):158
–71
. 8.
Harting
MT
, Lally
KP
. The congenital diaphragmatic hernia study group registry update
. Semin Fetal Neonatal Med
. 2014
;19
(6
):370
–5
. 9.
Montalva
L
, Lauriti
G
, Zani
A
. Congenital heart disease associated with congenital diaphragmatic hernia: a systematic review on incidence, prenatal diagnosis, management, and outcome
. J Pediatr Surg
. 2019
;54
(5
):909
–19
. 10.
Congenital diaphragmatic hernia and congenital heart disease
. AAP Grand Rounds
. 2023
;50
(3
):33
.11.
Lin
AE
, Pober
BR
, Adatia
I
. Congenital diaphragmatic hernia and associated cardiovascular malformations: type, frequency, and impact on management
. Am J Med Genet C Semin Med Genet
. 2007
;145C
(2
):201
–16
. 12.
Menon
SC
, Tani
LY
, Weng
HY
, Lally
PA
, Lally
KP
, Yoder
BA
, et al. Clinical characteristics and outcomes of patients with cardiac defects and congenital diaphragmatic hernia
. J Pediatr
. 2013
;162
(1
):114
–9.e2
. 13.
Graziano
JN
; Congenital Diaphragmatic Hernia Study Group
. Cardiac anomalies in patients with congenital diaphragmatic hernia and their prognosis: a report from the Congenital Diaphragmatic Hernia Study Group
. J Pediatr Surg
. 2005
;40
(6
):1045
–50
. 14.
Hari Gopal
S
, Patel
N
, Fernandes
CJ
. Use of prostaglandin E1 in the management of congenital diaphragmatic hernia–a review
. Front Pediatr
. 2022
;10
:911588
. 15.
Lawrence
KM
, Berger
K
, Herkert
L
, Franciscovich
C
, O’Dea
CLH
, Waqar
LN
, et al. Use of prostaglandin E1 to treat pulmonary hypertension in congenital diaphragmatic hernia
. J Pediatr Surg
. 2019
;54
(1
):55
–9
. 16.
Le Duc
K
, Mur
S
, Sharma
D
, Aubry
E
, Recher
M
, Rakza
T
, et al. Prostaglandin E1 in infants with congenital diaphragmatic hernia (CDH) and life-threatening pulmonary hypertension
. J Pediatr Surg
. 2020
;55
(9
):1872
–8
. 17.
Shiyanagi
S
, Okazaki
T
, Shoji
H
, Shimizu
T
, Tanaka
T
, Takeda
S
, et al. Management of pulmonary hypertension in congenital diaphragmatic hernia: nitric oxide with prostaglandin-E1 versus nitric oxide alone
. Pediatr Surg Int
. 2008
;24
(10
):1101
–4
. 18.
Abman
SH
, Hansmann
G
, Archer
SL
, Ivy
DD
, Adatia
I
, Chung
WK
, et al. Pediatric pulmonary hypertension: guidelines from the American heart association and American thoracic Society
. Circulation
. 2015
;132
(21
):2037
–99
. 19.
Ruano
R
, Lazar
DA
, Cass
DL
, Zamora
IJ
, Lee
TC
, Cassady
CI
, et al. Fetal lung volume and quantification of liver herniation by magnetic resonance imaging in isolated congenital diaphragmatic hernia
. Ultrasound Obstet Gynecol
. 2014
;43
(6
):662
–9
. 20.
Rios
DR
, Bhattacharya
S
, Levy
PT
, McNamara
PJ
. Circulatory insufficiency and hypotension related to the ductus arteriosus in neonates
. Front Pediatr
. 2018
;6
(March
):1
–12
. 21.
Lam
CF
, Peterson
TE
, Croatt
AJ
, Nath
KA
, Katusic
ZS
. Functional adaptation and remodeling of pulmonary artery in flow-induced pulmonary hypertension
. Am J Physiol Heart Circ Physiol
. 2005
;289
(6
):H2334
–41
. 22.
Pokharel
MD
, Marciano
DP
, Fu
P
, Franco
MC
, Unwalla
H
, Tieu
K
, et al. Metabolic reprogramming, oxidative stress, and pulmonary hypertension
. Redox Biol
. 2023
;64
:102797
. 23.
D'Alto
M
, Mahadevan
VS
. Pulmonary arterial hypertension associated with congenital heart disease
. Eur Respir Rev
. 2012
;21
(126
):328
–37
. 24.
Nawaytou
H
, Hills
NK
, Clyman
RI
. Patent ductus arteriosus and the risk of bronchopulmonary dysplasia-associated pulmonary hypertension
. Pediatr Res
. 2023
;94
(2
):547
–54
. 25.
Choi
EK
, Jung
YH
, Kim
HS
, Shin
SH
, Choi
CW
, Kim
EK
, et al. The impact of atrial left-to-right shunt on pulmonary hypertension in preterm infants with moderate or severe bronchopulmonary dysplasia
. Pediatr Neonatol
. 2015
;56
(5
):317
–23
. 26.
Gentle
SJ
, Travers
CP
, Clark
M
, Carlo
WA
, Ambalavanan
N
. Patent ductus arteriosus and development of bronchopulmonary dysplasia–associated pulmonary hypertension
. Am J Respir Crit Care Med
. 2023
;207
(7
):921
–8
. 27.
Villamor
E
, van Westering-Kroon
E
, Gonzalez-Luis
GE
, Bartoš
F
, Abman
SH
, Huizing
MJ
. Patent ductus arteriosus and bronchopulmonary dysplasia–associated pulmonary hypertension: a bayesian meta-analysis
. JAMA Netw Open
. 2023
;6
(11
):e2345299
. 28.
Webb
MK
, Cuevas Guaman
M
, Sexson Tejtel
SK
, Cambronero
N
, Coleman
RD
, Chartan
CA
, et al. Atrial septal defect closure is associated with improved clinical status in patients≤ 10 kg with bronchopulmonary dysplasia
. Pulm Circ
. 2023
;13
(4
):e12299
. 29.
Tanke
R
, Daniels
O
, Van Heyst
A
, Van Lier
H
, Festen
C
. The influence of ductal left-to-right shunting during extracorporeal membrane oxygenation
. J Pediatr Surg
. 2002
;37
(8
):1165
–8
. 30.
Bo
B
, Pugnaloni
F
, Licari
A
, Patel
N
, Strizek
B
, Lemloh
L
, et al. Ductus arteriosus flow predicts outcome in neonates with congenital diaphragmatic hernia
. Pediatr Pulmonol
. 2023
;58
(6
):1711
–8
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
